文献速递浆细胞疾病

CD38/CD3xCD28三特异性T细胞衔接器作为抗CD38单克隆抗体复发或难治性多发性骨髓瘤患者的潜在活性药物

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.
PubMed 文献 · Br J Haematol · 2024-09-22

本文为临床前研究,针对既往接受抗CD38单克隆抗体治疗后复发或难治的多发性骨髓瘤患者,探讨其对新型CD38/CD3xCD28三特异性T细胞衔接器SAR442257的潜在获益。原文指出此类患者虽无完全CD38丢失,但存在CD38表面表达下调和NK细胞数量与功能下降,对CD38单抗再治疗耐药。临床前证据提示,此类患者可能从较少依赖CD38抗原密度和NK细胞活性的T细胞免疫治疗中获益。

要点

  • 抗CD38单抗治疗后复发患者无完全CD38丢失,但CD38表面表达下调且NK细胞数量与功能下降。
  • 上述改变使患者对CD38单抗再治疗耐药。
  • 临床前证据提示SAR442257可能使既往暴露于抗CD38单抗的RRMM患者获益。

核心结论

  • 既往暴露于抗CD38单克隆抗体的复发或难治性多发性骨髓瘤患者可能从较少依赖CD38抗原密度和NK细胞活性的T细胞免疫治疗(如SAR442257)中获益,此为临床前证据。

研究设计与样本

  • 临床前研究,评估新型CD38/CD3xCD28三特异性T细胞衔接器SAR442257。

主要发现

  • 抗CD38单克隆抗体治疗后复发的患者中未观察到完全CD38丢失,但存在CD38表面表达下调和NK细胞数量与功能下降。
  • 上述CD38表达下调和NK细胞数量与功能下降使患者对CD38单克隆抗体再治疗耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is accumulating evidence of BCMA and GPRC5D loss after treatment with T-cell redirecting therapies in patients with relapsed/refractory multiple myeloma (RRMM). While complete CD38 loss is not observed upon relapses after treatment with anti-CD38 monoclonal antibodies (mAb), there is downregulation of surface CD38 expression and decreased number and function of NK cells, which renders these patients resistant to retreatment with anti-CD38 mAb. Here, we provide preclinical evidence that RRMM patients previously exposed to anti-CD38 mAb could benefit from T-cell-based immunotherapy that depend less on CD38 antigen density and NK-cell activity, such as the novel CD38/CD3xCD28 trispecific T-cell engager, SAR442257.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zabaleta A, Blanco L, Kim PS, et al. A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies. Br J Haematol. 2024. PMID: 39308023. doi:10.1111/bjh.19784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。